BR112019018593A2 - fagoterapia - Google Patents

fagoterapia Download PDF

Info

Publication number
BR112019018593A2
BR112019018593A2 BR112019018593A BR112019018593A BR112019018593A2 BR 112019018593 A2 BR112019018593 A2 BR 112019018593A2 BR 112019018593 A BR112019018593 A BR 112019018593A BR 112019018593 A BR112019018593 A BR 112019018593A BR 112019018593 A2 BR112019018593 A2 BR 112019018593A2
Authority
BR
Brazil
Prior art keywords
bacteriophage
bacteriophages
sequence
seq
identity
Prior art date
Application number
BR112019018593A
Other languages
English (en)
Portuguese (pt)
Inventor
Fevre Cindy
Blois Hélène
Medina Mathieu
Original Assignee
Pherecydes Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pherecydes Pharma filed Critical Pherecydes Pharma
Publication of BR112019018593A2 publication Critical patent/BR112019018593A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/40—Viruses, e.g. bacteriophages
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/50—Isolated enzymes; Isolated proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10131—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10231—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10271—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pest Control & Pesticides (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
BR112019018593A 2017-03-08 2018-03-07 fagoterapia BR112019018593A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17305245.7A EP3372085A1 (en) 2017-03-08 2017-03-08 Phage therapy
PCT/EP2018/055629 WO2018162566A1 (en) 2017-03-08 2018-03-07 Phage therapy

Publications (1)

Publication Number Publication Date
BR112019018593A2 true BR112019018593A2 (pt) 2020-04-28

Family

ID=58536918

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019018593A BR112019018593A2 (pt) 2017-03-08 2018-03-07 fagoterapia

Country Status (9)

Country Link
US (2) US11690885B2 (enExample)
EP (2) EP3372085A1 (enExample)
JP (2) JP7492337B2 (enExample)
CN (2) CN110545670B (enExample)
AU (2) AU2018231408B2 (enExample)
BR (1) BR112019018593A2 (enExample)
CA (1) CA3054874A1 (enExample)
IL (2) IL288099B (enExample)
WO (1) WO2018162566A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3372085A1 (en) 2017-03-08 2018-09-12 Pherecydes Pharma Phage therapy
WO2021146598A1 (en) * 2020-01-17 2021-07-22 Second Genome, Inc. Methods and compositions for treating atopic dermatitis
IL295408A (en) * 2020-02-18 2022-10-01 Armata Pharmaceuticals Inc Bacteriophage preparations for the treatment of staphylococcus infection
CZ309429B6 (cs) * 2020-03-31 2023-01-04 MB PHARMA s.r.o Lyofilizovaná testovací sada ke stanovení antimikrobiální biologické účinnosti fágových přípravků na bakterii Staphylococcus aureus
EP4132552A2 (en) * 2020-04-06 2023-02-15 Adaptive Phage Therapeutics, Inc. Method for treating implantable device infections
EP4337764A1 (en) * 2021-05-12 2024-03-20 Biomx Ltd. Staphylococcus bacteriophage and uses thereof
FR3161553A1 (fr) * 2024-04-30 2025-10-31 Hospices Civils De Lyon Compositions, en particulier, pharmaceutiques de bactériophages de la classe des Caudoviricetes , procédé et utilisations associés

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1690194A (zh) * 2004-04-26 2005-11-02 何俭 一株治疗金黄色葡萄球菌感染的噬菌体
GB0800149D0 (en) * 2008-01-04 2008-02-13 Novolytics Ltd Improved host range phage
EP2103308A1 (de) * 2008-03-20 2009-09-23 PhytoLine GmbH Verfahren zur Herstellung eines Gemisches von Bakteriophagen und deren Verwendung für die Therapie von Antibiotika-resistenten Staphylococcen
US7745194B2 (en) * 2008-09-16 2010-06-29 Intralytix, Inc. Staphylococcus aureus: bacteriophage and uses thereof
US8043613B2 (en) * 2009-02-12 2011-10-25 Intron Biotechnology, Inc. Podoviriedae bacteriophage having killing activity specific to Staphylococcus aureus
KR20130142820A (ko) 2012-06-20 2013-12-30 한국외국어대학교 연구산학협력단 스태필로코커스 아우레우스의 박테리오파아지 및 그 용도
EP2865383A1 (en) 2013-10-25 2015-04-29 Pherecydes Pharma Phage therapy of pseudomonas infections
EP2893933A1 (en) 2014-01-10 2015-07-15 Pherecydes Pharma Phage Therapy of E coli infections
EP3018201A1 (en) 2014-11-07 2016-05-11 Pherecydes Pharma Phage therapy
CN104845942A (zh) * 2015-04-22 2015-08-19 上海交通大学 可裂解多种耐药性金黄色葡萄球菌的噬菌体及其分离方法和用途
WO2017015652A1 (en) 2015-07-23 2017-01-26 Enbiotix, Inc. Bacteriophage for treating staphylococcus infections
CN105567647B (zh) * 2015-11-06 2019-06-11 中国海洋大学 一株耐甲氧西林金黄色葡萄球菌噬菌体及其抑菌应用
EP3372085A1 (en) 2017-03-08 2018-09-12 Pherecydes Pharma Phage therapy

Also Published As

Publication number Publication date
IL288099A (en) 2022-01-01
CN114107220A (zh) 2022-03-01
US12280080B2 (en) 2025-04-22
US20200030392A1 (en) 2020-01-30
AU2018231408B2 (en) 2023-07-27
JP7492337B2 (ja) 2024-05-29
CA3054874A1 (en) 2018-09-13
EP3592150A1 (en) 2020-01-15
WO2018162566A1 (en) 2018-09-13
IL268905A (en) 2019-10-31
AU2018231408A1 (en) 2019-09-12
JP2024105630A (ja) 2024-08-06
JP2020510024A (ja) 2020-04-02
IL268905B (en) 2021-12-01
AU2023251526A1 (en) 2023-11-16
CN114107220B (zh) 2025-01-10
EP3372085A1 (en) 2018-09-12
CN110545670A (zh) 2019-12-06
US11690885B2 (en) 2023-07-04
IL288099B (en) 2022-07-01
CN110545670B (zh) 2021-11-23
US20240024391A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
US20240366694A1 (en) Phage therapy of e coli infections
US11779617B2 (en) Phage therapy
US12280080B2 (en) Antibacterial composition and uses thereof
US10260051B2 (en) Phage therapy of Pseudomonas infections
BR112016015996B1 (pt) Composição antibacteriana, método para a preparação de uma composição, método in vitro para prever ou determinar a eficácia de uma terapia de bacteriófago em um indivíduo, e método in vitro para selecionar um indivíduo ou determinar se um indivíduo é suscetível de se beneficiar de uma terapia com bacteriófagos
BR122022026618B1 (pt) Composição antibacteriana, método para a preparação de uma composição, método in vitro para prever ou determinar a eficácia de uma terapia de bacteriófago em um indivíduo, e método in vitro para selecionar um indivíduo ou determinar se um indivíduo é suscetível de se beneficiar de uma terapia com bacteriófagos
HK1227712A1 (en) Phage therapy of pseudomonas infections
HK1227712B (en) Phage therapy of pseudomonas infections

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A01N 63/00 , A61K 35/76 , C07K 14/01 , C12N 7/00

Ipc: A61K 35/76 (2015.01), A01N 63/00 (2020.01), C07K 1

B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: ERYTECH PHARMA (FR)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements